

SmartPA Criteria Proposal

	Pulmonary Arterial Hypertension (PAH) Agents, Phosphodiesterase-5 (PDE5) and Soluble Guanylate Cyclase (SGC) Stimulators PDL Edit
	June 25, 2008
	September 16, 2021
	MO HealthNet
	MO HealthNet/Conduent
	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Pulmonary arterial hypertension (PAH) is a severe, progressive, and often fatal condition that occurs idiopathically as well as in association with pulmonary, cardiac, and other thoracic conditions. Reliable estimates of the total prevalence of this condition are difficult to obtain because of the diversity of identifiable causes. PAH, formerly known as primary pulmonary hypertension, is characterized by elevations in pulmonary arterial pressure (PAP) to greater than 25 mmHg at rest and greater than 30 mmHg with exercise. The disease occurs when the PAP is abnormally elevated and forces the right side of the heart to progressively work harder when it pumps blood to the lungs. Symptoms include dyspnea, fatigue, chest pain, palpitations, syncope, and edema. Prognosis varies based on the severity of disease, whether right heart failure is present, and response to vasodilator therapy. If left untreated, the disease produces increases in PAP that may lead to right ventricular failure and death. Despite recent developments in the symptomatic treatment of PAH, there is still no cure.

PAH should be differentiated from pulmonary hypertension secondary to diseases of the heart and lung based on both pathology of the underlying disease and accepted treatments.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Sildenafil Inj/Tabs (gen Revatio®) Tadalafil Tabs (gen Adcirca®) 	<ul style="list-style-type: none"> Adcirca® Adempas® Alyq™ Revatio® Sildenafil Susp

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Pulmonary Arterial Hypertension (PAH) Agents, Phosphodiesterase-5 (PDE5) and Soluble Guanylate Cyclase (SGC) Stimulators
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Documented diagnosis of pulmonary hypertension **AND**
- Documented compliance on current therapy regimen **OR**
- For injectable Revatio: failure to achieve desired therapeutic outcomes with trial of 2 or more preferred agents, with one being generic sildenafil injection **AND**
- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents
- For Adempas:
 - Documented diagnosis of chronic thromboembolic pulmonary hypertension **OR**
 - **Trial of 1 preferred agent OR**
 - **Documented ADE/ADR to preferred agents**
- Claim exceeds minimum dosing limitations for the following:

Drug Description	Generic Equivalent	Minimum Dosing Limitation
REVATIO 10 MG/12.5 ML VIAL	SILDENAFIL	3 vials per day
REVATIO 10 MG/ML ORAL SUSP	SILDENAFIL	6 mL per day
REVATIO 20 MG TABLET	SILDENAFIL	3 tablets per day

Denial Criteria

- **History of nitrate therapy within the last 45 days**
- For Adempas: participant is currently pregnant
- For Revatio: history of ritonavir (Norvir or Kaletra) therapy within the last **45** days
- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

References

1. Evidence-Based Medicine and Fiscal Analysis: “PAH-PPH” – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; July 2021.
2. Evidence-Based Medicine Analysis: “Primary Pulmonary Arterial Hypertension (PAH) Agents”, UMKC-DIC; June 2021.
3. Lajoie A, Bonnet S, Provencher S. Review Article: Combination Therapy in Pulmonary Arterial Hypertension: Recent accomplishments and future challenges. *Pulmonary Circulation* 2017; 7(2) 312–325.
4. USPDI, Micromedex; 2021.
5. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.
6. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults 2018: update of the CHEST Guideline and Expert Panel Report. *Chest*. 2019; 155(3): 565-586.
7. Revatio [package insert]. New York, NY: Pfizer Labs; February 2020.
8. Adcirca [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2020.
9. Adempas [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; January 2018.